Skip to main content
Premium Trial:

Request an Annual Quote

Trying to Rise from the Dead

While Decode Genetics was able to find many links between genes and disease, "what it didn't find, however, was a business model that made sense," says this Newsweek article, and Decode went bankrupt in November. The company, however, is trying to rise from the ashes with an investment from Saga. The new CEO, Earl Collier is trying to turn Decode into a consulting company that would analyze researchers' sequencing data and "[give] it back in a nicely packaged way."

Daniel MacArthur points out that the article "gives the strong impression that the days of [deCODEme] are well and truly numbered" – Collier says that "if you want one, you'd better buy it now."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.